David Grainger PhD

Morphogen-IX The Board


After spending 15 years at Cambridge University leading an internationally-recognised laboratory investigating the causes of coronary heart disease, David founded Funxional Therapeutics.

Here he became the Chief Scientific Officer, developing FX125L, a novel anti-inflammatory agent for the treatment of asthma and other diseases with a chronic inflammatory component.

Following the sale of FX125L in July 2012, David joined Index Ventures as a Venture Partner, where he was responsible for the creation, development and sale of XO1 and the creation of E3Bio.

Developing BMPs as novel treatments for pulmonary arterial hypertension